Status:
COMPLETED
Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract
Lead Sponsor:
Pierre Fabre Medicament
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Transitional Cell Carcinoma of the Urothelial Tract
Bladder Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this clinical research study is to learn if patients who receive vinflunine plus best supportive care live longer than patients who receive best supportive care alone. This study will a...
Eligibility Criteria
Inclusion
- Bladder cancer
- Progressed after 1st line platinum-chemotherapy
- \>= 18 years old
- Adequate hematologic, hepatic \& renal function
Exclusion
- CNS disease
- Moderate neuropathy
- More than 1 previous chemotherapy
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2008
Estimated Enrollment :
364 Patients enrolled
Trial Details
Trial ID
NCT00315237
Start Date
July 1 2005
End Date
January 1 2008
Last Update
January 7 2010
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Calgary, Alberta, Canada
2
Local Institution
Edmonton, Alberta, Canada
3
Local Institution
Vancouver, British Columbia, Canada
4
Local Institution
Victoria, British Columbia, Canada